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Abstract
Aim Hypoglycaemia in Type 1 diabetes is associated with mortality and morbidity, especially where awareness of
hypoglycaemia is impaired. Clinical pathways for access to continuous glucose monitoring (CGM) and flash glucose
monitoring technologies are unclear. We assessed the impact of CGM and flash glucose monitoring in a high-risk group
of people with Type 1 diabetes.
Methods A randomized, non-masked parallel group study was undertaken. Adults with Type 1 diabetes using a
multiple-dose insulin-injection regimen with a Gold score of ≥ 4 or recent severe hypoglycaemia were recruited.
Following 2 weeks of blinded CGM, they were randomly assigned to CGM (Dexcom G5) or flash glucose monitoring
(Abbott Freestyle Libre) for 8 weeks. The primary outcome was the difference in time spent in hypoglycaemia (below
3.3 mmol/l) from baseline to endpoint with CGM versus flash glucose monitoring.
Results Some 40 participants were randomized to CGM (n = 20) or flash glucose monitoring (n = 20). The
participants (24 men, 16 women) had a median (IQR) age of 49.6 (37.5–63.5) years, duration of diabetes of 30.0 (21.0–
36.5) years and HbA1c of 56 (48–63) mmol/mol [7.3 (6.5–7.8)%]. The baseline median percentage time < 3.3 mmol/l
was 4.5% in the CGM group and 6.7% in the flash glucose monitoring. At the end-point the percentage time
< 3.3 mmol/l was 2.4%, and 6.8% respectively (median between group difference 4.3%, P = 0.006). Time spent in
hypoglycaemia at all thresholds, and hypoglycaemia fear, were different between groups, favouring CGM.
Conclusion CGM more effectively reduces time spent in hypoglycaemia in people with Type 1 diabetes and impaired
awareness of hypoglycaemia compared with flash glucose monitoring. (Clinical Trial Registry No: NCT03028220)
Diabet. Med. 00, 00–00 (2017)
Introduction
Type 1 diabetes accounts for 10–15% of the worldwide
diabetes prevalence and its incidence is increasing worldwide
by 3–5% percent annually [1]. Achieving optimal glucose
control, as measured by HbA1c, reduces the risk of micro-
and macrovascular complications, but can be challenging for
people living with Type 1 diabetes due to hypoglycaemia
[2–4].
Hypoglycaemia is a metabolic complication of Type 1
diabetes and is one of the major barriers to optimizing
glucose self-management. People with Type 1 diabetes on
average have 1.8 self-treated incidences of hypoglycaemia
per week, and 0.2–3.2 episodes of severe hypoglycaemia,
defined as hypoglycaemia requiring the assistance of a third
party, annually [5,6]. Recurrent hypoglycaemia erodes
hypoglycaemia awareness and impaired awareness is seen
in around a quarter of people with Type 1 diabetes [7].
However, this may be an underestimate, with self-reported
severe hypoglycaemia rates affected by driving regulations
and other considerations [8].
Impaired awareness of hypoglycaemia increases risk of
severe hypoglycaemia six-fold. Hypoglycaemia is one of the
postulated causes of the ‘dead in bed’ syndrome, which is the
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leading cause of death in people under 40 years of age with
Type 1 diabetes [9,10]. There is a three- to four-fold higher
mortality in people with diabetes who self-reported severe
hypoglycaemia in the preceding 5 years [11]. Hypoglycaemia
is, and remains, a significant burden for people with Type 1
diabetes and carries with it mortality and morbidity.
Continuous glucose monitoring (CGM) devices display an
estimate of blood glucose, along with the trends in glucose
changes, in real time. In addition, they provide alert and
alarm features for hypo- and hyperglycaemia, and for times
of rapid glucose change. Use of CGM is associated with a
reduction in HbA1c [12], and reduced exposure to, and risk
of hypoglycaemia [13] in people using insulin pump and
multiple-dose injection regimens [14]. The impact on glucose
and hypoglycaemia outcomes has additionally been con-
firmed in people with Type 1 diabetes and impaired
hypoglycaemia awareness [15]. Flash glucose monitoring
does not provide real-time data with alerts and alarms, but
allows users to retrospectively review the preceding 8 h of
continuous glucose data, along with a contemporary esti-
mated blood glucose value and trend line. The glucose data
are made available when the user chooses to swipe the reader
over the sensor. In one study of people with Type 1 diabetes,
flash glucose monitoring was associated with a reduction in
time spent in hypoglycaemia in people with Type 1 diabetes
and an HbA1c close to target [16].
International guidance supports the use of CGM for
people with Type 1 diabetes [17], especially those at high
risk of hypoglycaemia [18]. However, the role of flash
glucose monitoring in the self-management of Type 1
diabetes is less clear, especially for people with impaired
awareness of hypoglycaemia, or at high risk of severe
hypoglycaemia, and despite uptake of flash glucose moni-
toring led by people with diabetes, evidence-based clinical
pathways to optimize access to the appropriate monitoring
technologies are not available.
This study aims to assess the impact of CGM and flash
glucose monitoring on hypoglycaemia in people with Type 1
diabetes and impaired awareness of hypoglycaemia using a
multiple-dose insulin injection regimen.
Methods
Study design and participants
This randomized, non-masked parallel group study was
conducted at a single specialist site in the United Kingdom
(UK). Ethical approval was obtained from the National
Health Service (NHS) Research Ethics Committee. Partici-
pants aged ≥ 18 years with Type 1 diabetes for > 3 years
were recruited. In addition, participants had experienced a
severe hypoglycaemic event in the last 12 months requiring
third-party assistance or had a Gold score of ≥ 4. Those with
severe hypoglycaemia and a Gold score of < 4 may not have
impaired hypoglycaemia awareness; however, severe hypo-
glycaemia is associated with impaired awareness of hypogly-
caemia and they have therefore been included in this high-risk
study population. They had been using an intensified multi-
ple-dose insulin injection regimen for over 6 months and a
diagnosis of Type 1 diabetes was confirmed based on clinical
features and a fasting c-peptide < 200 pmol/l. All participants
had received Type 1 diabetes education, including the
principles of flexible insulin therapy, either as a group or in
a one-to-one environment from a specialist educator. Partic-
ipants were excluded if they had used CGM or flash glucose
monitoring within the last 6 months (except short periods of
diagnostic blinded use under clinic supervision), used regular
paracetamol, were pregnant or planning pregnancy, breast-
feeding, enrolled in other clinical trials, had active malig-
nancy or were under investigation for malignancy, had severe
visual impairment, or reduced manual dexterity. All partic-
ipants gave written informed consent.
Procedures
At study enrolment, participants gave a full medical and
medication history, and underwent a physical examination
and electrocardiogram. Fasting venous blood tests were
taken to assess HbA1c, plasma glucose, urea and electrolytes,
cortisol, and serum c-peptide. Women of childbearing age
had a urine pregnancy test. The Gold Score, Hypoglycaemia
Fear Score II (HFS-II), and Problem Areas in Diabetes (PAID)
questionnaires were completed. The Gold score is given by
subjective rating on a scale from 1 (always) to 7 (never) in
response to the question ‘Do you know when your hypos are
commencing?’. Participants meeting the inclusion criteria
had a brief Type 1 diabetes education refresher. Participants
then commenced a two-week run-in phase using the Dexcom
What’s new?
• This is the first head-to-head glucose monitoring study
comparing continuous glucose monitoring (CGM) and
flash glucose monitoring. This study addresses the
highest risk group with problematic and severe hypo-
glycaemia.
• CGM has a greater beneficial impact on hypoglycaemia
outcomes than flash glucose monitoring for people at
high risk of hypoglycaemia.
• The data contribute to the existing CGM literature and
are the first for flash glucose monitoring in a high-risk
group, expanding the evidence base.
• The results are clinically relevant and support a role for
CGM in the clinical pathway in people with severe
hypoglycaemia or impaired awareness of hypogly-
caemia.
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(San Diego, CA, USA) G4 sensor with a blinded receiver
running the advanced ‘505’ algorithm which stores glucose
data, but does not make it available to the participant. The
sensor was calibrated to capillary blood glucose values a
minimum of twice daily. From these blinded CGM data
baseline glucose metrics were calculated.
Participants were randomly assigned to CGM (Dexcom
G5) or flash glucose monitoring (Abbott Freestyle Libre) in a
1 :1 ratio using an online randomization tool (www.sealede
nvelope.com). Randomization was stratified by HbA1c
(< 58 mmol/mol and ≥ 58 mmol/mol). The treatment period
was 8 weeks.
Participants then received standardized CGM education for
the CGM (Dexcom G5) or flash glucose monitoring (Abbott
Freestyle Libre) devices, including the use of the absolute
value, rate of change arrow and glucose trend line. Both the
CGM and flash glucose monitoring systems were used non-
adjunctively (without capillary blood glucose verification
before making a treatment decision), in accordance with
product licences but participants were instructed to test their
capillary blood glucose if symptoms of hypo- or hypergly-
caemia occur, in case of sensor failure or if the sensor glucose
is out of the device’s range. Participants used the sensors with
the accompanying receivers and changed the sensor according
to the license (every 7 days for Dexcom G5, every 14 days for
Freestyle Libre) or sooner in the event of sensor failure. There
was a telephone visit 2 weeks after randomization focusing
on the function of the technology and any difficulties with
use. Participants attended the clinical research facility
4 weeks after randomization and data were downloaded
from their CGM and flash glucose monitoring devices using
the Diasend software. Eight weeks after randomization
participants attended the clinical research facility for a
venous blood test for HbA1c. They additionally completed
the Gold Score, HFS-II and PAID questionnaires, and data
were downloaded from their CGM and flash glucose mon-
itoring devices. Participants were provided with a contact
number for technical support, but insulin titration decisions
were made by the participant throughout the study. In the
CGM arm of the study, low glucose alert settings were
standardized at 4.4 mmol/l for all participants at randomiza-
tion and could be reduced to 4 mmol/l at week 2 during the
telephone visit depending on participant preference. High
glucose alerts were not protocolized.
Outcomes
The primary outcome was change in time spent in hypogly-
caemia (< 3.3 mmol/l) from baseline to endpoint with CGM
vs. flash glucose monitoring. Secondary outcomes were
percentage time spent in hypoglycaemia < 2.8, 3.5 and
3.9 mmol/l, percentage time in euglycaemia (3.9–7.8 mmol/l),
percentage time spent in target (3.9–10 mmol/l), percentage
time spent inhyperglycaemia> 7.8,> 10and> 15 mmol/l, low
blood glucose index (LBGI, a measure of hypoglycaemia risk
derived from continuous glucose data), severe hypoglycaemia
(requiring third-party assistance to treat), hypoglycaemia risk,
HbA1c,Gold Score, hypoglycaemia fear (HFS-II) and diabetes-
related emotional distress (PAID questionnaire). Baseline
continuous glucose data were taken from the first 14 days of
monitoring (the run-in phase) and endpoint outcomes calcu-
lated from the last 28 days in each treatment period.
Statistical analysis
In this pilot study we recruited n = 20 in each group (40
participants in total) which would demonstrate as significant
(P < 0.05) at 80% power a 0.92 standard deviation differ-
ence in mean change from baseline, in percentage time in
hypoglycaemia (< 3.3 mmol/l), between CGM and flash
glucose monitoring. Data were analysed using Stata v14
(StataCorp, College Station, TX, USA). Many variables were
not normally distributed and summary statistics are therefore
presented as median (IQR) and median change (95%
confidence interval). Outcomes at baseline and at 8 weeks
were analysed for CGM and for flash glucose monitoring
separately, and change from baseline to 8 weeks was
compared between the two interventions. The primary
outcome comparison was between CGM and flash glucose
monitoring in change in percentage time in hypoglycaemia
(< 3.3 mmol/l). Secondary outcome comparisons were con-
sidered as hypothesis-generating and informative. The Wil-
coxon rank sum test was used for comparing median changes
between groups. Analysis was by intention to treat. No data
monitoring committee was convened. The study is registered
at ClincialTrials.gov, number NCT03028220.
Results
We recruited 47 participants between 22 January 2016 and 7
December 2016. Seven participants were excluded and 40
were subsequently randomized to CGM (n = 20) or flash
glucose monitoring (n = 20) following the baseline run-in
period (Fig. 1, Table 1). Participants (24 men, 16 women)
had a median (IQR) age of 49.5 (37.5–63.5) years, duration
of diabetes of 30.0 (21.0–36.5) years, HbA1c of 56 (48–
63) mmol/mol (7.3 (6.5–7.8)%), Gold Score of 5 (4–5), and
episodes of self-reported hypoglycaemia per week of 3.0
(2.0–4.5). There were no significant differences in baseline
characteristics between the groups. Some 39 of the 40
participants included had a history of at least one episode of
severe hypoglycaemia in the past (6 months to 7 years ago).
Five participants were randomized with a history of severe
hypoglycaemia in the preceding year (and a Gold score of
< 4), all other participants had a Gold score of ≥ 4. Those
with a Gold score of < 4 all had a Gold score of 3 at baseline.
Two of these participants were randomized to the CGM
group and the remaining three to the flash glucose monitor-
ing group. All 40 randomized participants completed the
intervention period. For outcomes derived from CGM data
ª 2017 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 3
Research article DIABETICMedicine
n = 19 were analysed in the CGM group due to loss of the 8-
week CGM data for one participant resulting from uploading
error. A comparison of the glucose outcomes, derived from
the run-in blinded CGM data, between the CGM and flash
glucose monitoring groups was performed (using a non-
parametric test) and showed no statistical difference between
groups at baseline. None of the participants or their family/
friends downloaded the Dexcom Share app which allows
family members and friends to follow glucose trends and
alarms of the individual.
Median percentage time < 3.3 mmol/l fell from 4.5% to
2.4% in the CGM group and changed from to 6.7% to 6.8%
in the flash glucose monitoring group (Table 2). For the
primary outcome comparison, the median changes from
baseline to end-point for participants using CGM and flash
glucose monitoring were 3.0% and +1.3%< respectively
(P = 0.006). Accordingly, the median net effect of CGM
relative to flash glucose monitoring was a reduction of 4.3%
in percentage time < 3.3 mmol/l.
Within-group changes and significance levels for between
group differences for all CGM outcomes are reported in
Table 2. The same directionality of change and between-
group differences were found for hypoglycaemia outcomes
when overnight CGM data only (22:00 h to 07:00 h) were
analysed (Table 3). No significant between group differences
in change in time in target or in time spent above hypergly-
caemic thresholds were observed.
No episodes of severe hypoglycaemia were reported during
the 8-week intervention phase in either group.
At baseline 90% (18/20) of participants in the CGM group
and 85% (17/20) had a Gold score ≥ 4; at the 8-week end-
point this was reduced to 60% (12/20) in both groups,
indicating restored self-reported hypoglycaemia awareness in
a proportion of individuals. However, no significant differ-
ence was observed in overall Gold score from baseline to
end-point between the two groups (Table 4). No between-
group differences in HbA1c change were noted at 8 weeks.
The change in hypoglycaemia between group difference
was significant (P = 0.02; Table 4). This difference was
accounted for by changes in the worry sub-score of the HFS-
II (P = 0.02 for the between group difference). No within or
between group differences were noted in HFS-II behaviour
sub-score, and PAID scores.
Discussion
The results from this randomized parallel group pilot study
suggest that an 8-week intervention with CGM has a greater
benefit in reducing time in hypoglycaemia comparedwith flash
glucose monitoring in people with Type 1 diabetes and
impaired awareness of hypoglycaemia. Both CGM and flash
glucosemonitoring improvedHbA1c andpercentage time spent
in glucose target (3.9–7.8 and 3.9–10 mmol/l) over 8 weeks.
Finally, within- and between-group improvements in overall
Assessed for eligibility n = 47
Randomized n = 40
Allocated to CGM
n = 20 
Allocated to flash glucose
monitoring n = 20
Analysed n = 20* Analysed n = 20
7 participants excluded†
FIGURE 1 Participant recruitment. Results are expressed as median (IQR). *For outcomes derived from continuous glucose monitoring (CGM) data,
n = 19 were analysed in the G5 group due to loss of the 8-week CGM data for one participant (uploading error). †Reasons for participant exclusion
were: severe hypoglycaemia in run-in (1), failed to comply with visit schedule (3), dropped out due interference of study with exercise programme
(1), dropped out as they did not feel they could commit to the study (2).
Table 1 Baseline characteristics of study participants. Results are expressed as median (IQR)
CGM (n = 20) Flash glucose monitoring (n = 20) All participants (n = 40)
Gender (male : female) 12 : 8 12 : 8 24 : 16
Age (years) 50.5 (45.0–64.5) 48.5 (34.0–63.0) 49.5 (37.5–63.5)
Duration of diabetes (years) 30.0 (25.0–36.0) 28.0 (16.5–36.5) 30.0 (21.0–36.5)
Gold score 5 (5–6) 5 (4–5) 5 (4–5)
HbA1c (mmol/mol) 57 (49–62) 55 (48–65) 56 (48–63)
HbA1c (%) 7.4 (6.6–7.8) 7.2 (6.5–8.1) 7.3 (6.5–7.8)
Self-reported hypoglycaemia/week 3.0 (2.0–4.0) 2.5 (1.7–4.7) 3.0 (2.0–4.5)
CGM, continuous glucose monitoring.
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hypoglycaemia fear and the worry sub-scale of the hypogly-
caemia fear survey were seen with CGM. Awareness of
hypoglycaemia remained unchanged with both glucose mon-
itoring devices.
This is the first direct comparator study of continuous
glucose recording technologies assessing glucose outcomes
and aimed to provide supporting evidence for clinical
pathways implementing CGM and flash glucose monitoring
technologies. Around 25% of people with Type 1 diabetes
have impaired awareness of hypoglycaemia, and the associ-
ations with severe hypoglycaemia confer a burden of
mortality and morbidity. The data from this study suggest
that alerts and alarms are important for this high-risk group,
and that evidence-based clinical pathways must include a
measure of hypoglycaemia awareness prior to implementing
monitoring technologies where flash glucose monitoring may
not be first choice. A measure of hypoglycaemia awareness is
already included in the National Institute for Health and
Care Excellence (NICE) guideline for Type 1 diabetes in
adults [18]. In the IMPACT study [16] flash glucose
monitoring reduced time in hypoglycaemia, a finding we
have not replicated, but IMPACT excluded people with
impaired awareness of hypoglycaemia and recruited partic-
ipants with a lower mean HbA1c. These differences in the
population recruited may further indicate the importance of
selecting the appropriate technology for individuals with
Type 1 diabetes.
We did not see an improvement in self-reported awareness
of hypoglycaemia measured by Gold score with either CGM
or flash glucose monitoring. The lack of improvement in
Gold score with CGM is consistent with findings seen in the
IN CONTROL study [15] and in a retrospective audit [19].
The HypoCOMPaSS study showed that restoration of
hypoglycaemia awareness can be achieved, but that self-
monitoring capillary blood glucose and CGM have an
equivalent effect on impaired awareness of hypoglycaemia
[20]. However, the study designs and technologies imple-
mented differ, and further research is warranted to explore
the impacts of technology as an adjunct to education in
people with Type 1 diabetes and impaired awareness of
hypoglycaemia. A limitation to evaluating the Gold score
after the use of CGM or flash glucose monitoring is that it is
a subjective score and therefore does not distinguish whether
those who restored their hypoglycaemia awareness had true
recurrence of hypoglycaemia awareness from symptoms or
whether the glucose monitoring was providing ‘electronic
awareness’ by seeing the glucose trace falling or hearing the
alarms with CGM.
Our study is limited by small numbers and a short follow-
up period, but the population and study design are compa-
rable with previous reports in highly selected high-risk
groups. The baseline estimate of glucose data was derived
from blinded CGM in both groups, but the final glucose data
was derived from either CGM or flash glucose monitoring.
Therefore, a further limitation is the comparison betweenTa
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CGM and FGM data, where accuracy may not be equiva-
lent, so glucose outcomes may not be directly comparable.
This applies when evaluating the difference from baseline to
endpoint within the flash glucose monitoring group and
when comparing the two groups. However, the devices were
used in line with license and the relative published accura-
cies, expressed as a mean absolute difference, are between
11% and 13% for real-world use [21–24]. Another limita-
tion of our study is that stratification at randomization was
based on HbA1c alone and does not consider other factors
such as age, gender and diabetes duration. It is also
important to note that the reported times within range
reported are not independent (for example the percentage
time spent < 3.3mmol outcome includes percentage time
spent < 2.8 mmol/l). We recognize that the inclusion of
participants with severe hypoglycaemia and a Gold score of
< 4 makes the study population heterogeneous as those five
participants with a Gold score of < 4 may not have impaired
awareness of hypoglycaemia. This is a limitation, but these
participants belong to a high-risk population and were
randomized in an equal distribution (two in the CGM group
and five in the flash glucose monitoring group). The strength
of the study lies in its novelty and the clearly defined
homogeneous group of those at highest risk of challenging
hypoglycaemia.
A new consensus for reporting hypoglycaemia in studies as
< 3.0 mmol/l was recently recommended by The Interna-
tional Hypoglycaemia Study Group [25], but this was not the
case at the time of study design. The percentage time spent at
glucose < 3.0 mmol/l was therefore not a predetermined
study outcome in this study, but when analysed post hoc the
baseline vs. endpoint values were (3.1 vs. 1.5) and (4.7 vs.
5.0) in the CGM group and flash glucose monitoring group
respectively and there was a significant difference in median
change from baseline between groups (P = 0.004), suggest-
ing benefit with CGM.
The uptake of flash glucose monitoring has been striking
but, as yet, the technology has not been widely incorporated
into clinical guidelines where its role has been unclear. The
IMPACT study selected a specific group of people with
HbA1c values close to target and showed no change in HbA1c
but a reduction in time spent in hypoglycaemia compared
with self-monitoring of capillary blood glucose [16]. This
study adds to the IMPACT and DIAMOND studies and
suggests that CGM is preferable to flash glucose monitoring
for people with Type 1 diabetes using a multiple-dose
injection regimen with HbA1c values above target, and for
those with challenging hypoglycaemia.
One possible mechanism for the findings in our study is the
impact of alerts and alarms on behaviour and it is striking to
note that, alongside a reduction in exposure to hypogly-
caemia, we have demonstrated a reduction in hypoglycaemia
fear and worry. The changes to hypoglycaemia fear should
be confirmed in a larger study with a more heterogeneous
population.
Conclusion
In summary, our pilot data suggest that CGM has a
greater beneficial impact on hypoglycaemia outcomes
than flash glucose monitoring for people with impaired
hypoglycaemia awareness. Additionally, CGM has a
beneficial impact on hypoglycaemia fear, one of the
major barriers to optimal glucose control. The data
suggest that careful assessment of hypoglycaemia aware-
ness is critical to selecting the appropriate glucose
monitoring technology and that evidence-based clinical
pathways for monitoring should be different for people
with impaired awareness.
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